Akums Drugs and Pharmaceuticals

Akums Drugs and Pharmaceuticals Limited
Akums
TypePublic
NSE: AKUMS BSE: 544222
ISININE09XN01023
IndustryPharmaceuticals, CDMO & Skincare
Founded2004 ; 21 years ago
HeadquartersDelhi, India
Area served
Worldwide
Key people
Sandeep Jain
(Founder and Managing Director)

Sanjeev Jain
(Founder & Managing Director)

Arushi Jain
(Director)
Products
RevenueIncrease ₹1,538.75 crore (US$160 million) (FY24)
Total assetsIncrease ₹2,095.43 crore (US$220 million) (FY24)
Number of employees
10,000+ (2024)
Subsidiaries
  • Akumentis Healthcare Limited.
  • Pure And Cure Healthcare Private Limited.
Websitewww.akums.in

Akums Drugs and Pharmaceuticals Limited (Akums Group) is an Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) that serves both domestic and multinational pharmaceutical companies.[1][2] The company was established in 2004 and became publicly listed on 6 August 2024.[3]

History

Akums was founded by Sanjeev Jain and Sandeep Jain in 2004, who currently serve as the managing directors of the company.[4] The company has 12 manufacturing facilities for various formulations and two facilities for producing active pharmaceutical ingredients (APIs).[5] It produces tablets, capsules, soft gels, dry syrups, liquid orals, and other pharmaceutical products.[6] Akums also operates four research and development (R&D) centers in India.[7] In 2020, the company received an investment of Rs 500 crore from Quadria Capital.[6]

In April 2022, the company acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited.[8] In May, the company received a license to manufacture and commercialize Bempedoic acid, a drug used to lower cholesterol. Two of the company's units in Haridwar were granted European GMP certification. One unit produces solid oral dosage forms, such as tablets and hard gelatin capsules, while the other manufactures large and small volume parenterals, including vials, ampoules, eye drops, and FFS formulations.[9] In August 2024, the company went public with a listing on the Bombay Stock Exchange and the National Stock Exchange.[3] In May 2025, Akums received a patent for an extended-release combination formulation of Doxylamine and Pyridoxine, indicated for the management of nausea and vomiting in pregnancy.[10]

In July and September 2025, Akums received Good manufacturing practice (GMP) certifications for its manufacturing facilities in Haridwar, including from Brazilian Health Regulatory Agency and the Eurasian Economic Union (EAEU) for its hormonal therapy unit.[11][12] In January 2026, two of its facilities in Haridwar, Uttarakhand, received European Union GMP certification issued by the Bulgarian Drug Agency (BDA).[13]

In November 2025, a 20-year patent for Dual Release Gastro-Resistant Composition effective from 19 November 2022, was granted to the company under the Patents Act, 1970.[14]

In February 2026, it received approval from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) to market rivaroxaban, an anticoagulant, in the country.[15]

See also

References

  1. ↑ Mishra, Mihir (30 April 2023). "Akums Drugs plans IPO within 3 years". mint.
  2. ↑ "Akums Drugs and Pharmaceuticals Ltd. - Analyst Research Report" (PDF). SBIsecurities.
  3. 1 2 Kumar Nahar, Pawan (6 August 2024). "Akums Drugs & Pharma shares list at 7% premium on BSE, NSE". Business Today.
  4. ↑ "Akums Drugs and Pharmaceuticals Limited - Analyst Research Report" (PDF). HDFCsec.
  5. ↑ "Akums buys new facility in Baddi to augment tablet output". BusinessLine. 5 December 2023.
  6. 1 2 "Quadria Capital-backed Akums, India's largest contract manufacturer of drugs, kicks off 2024 IPO plans". Moneycontrol. 23 September 2023.
  7. ↑ Somvanshi, Kiran (30 July 2024). "Akums Pharma placed at a vantage point in pharma growth". The Economic Times. ISSN 0013-0389.
  8. ↑ "Akums acquires drug manufacturing facility from Ankur Drugs - ET HealthWorld | Pharma". ETHealthworld.com | Pharma.
  9. ↑ "Akums receives EU GMP approval for two manufacturing units in Haridwar - ET HealthWorld". ETHealthworld.com.
  10. ↑ Singh, Anjali (5 May 2025). "Akums secures patent for dual-action nausea drug for pregnant women". www.business-standard.com. Archived from the original on 24 February 2026. Retrieved 29 March 2026.
  11. ↑ "Akums secures Anvisa GMP certification for Haridwar plant to boost Brazil, LatAm exports". BusinessLine. 28 July 2025. Retrieved 22 April 2026.
  12. ↑ "Akums' hormonal drug plant receives Eurasian Union nod". ETPharma.com. Retrieved 22 April 2026.
  13. ↑ "Akums secures EU GMP certificate for two manufacturing units". ETPharma.com. Retrieved 22 April 2026.
  14. ↑ "Akums Drugs gets 20- year patent for". indianpharmapost. Retrieved 22 April 2026.
  15. ↑ "Akums secures blood thinner Rivaroxaban marketing approval in UK". ETPharma.com. Retrieved 22 April 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.